ABSTRACT
Las exacerbaciones agudas de la EPOC son desencadenadas principalmente por infecciones bacterianas. Recientemente se ha revisado la racionalidad para la selección de antibióticos y se ha propuesto el empleo de ciproflaxacino como alternativa terapéutica. El objetivo de este trabajo fue evaluar la eficacia clínica y microbiológica del ciprofloxacino 750 mg (Baycip Bayer) 2 veces al día durante 9 días en pacientes EPOC con exacerbación aguda. Se realizó un estudio prospectivo, longitudinal, abierto no comparativo, multicéntrico en 57 pacientes. Existió cura clínica en 52 (96,3 por ciento) al día 10 y 49 (90,7 por ciento) al día 21. La eficacia microbiológica se midió en los 17 pacientes con cultivo positivo en la visita inicial. Hubo erradicación bacteriológica en 16 pacientes al día 10 y en 14 al día 21. Hubo 15 eventos adversos, 6 con relación posible o probable con la droga. Ciprofloxacino oral puede ser considerado un antibiótico útil en el tratamiento de las exacerbaciones agudas de EPOC
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Ciprofloxacin/pharmacology , Lung Diseases, Obstructive/drug therapy , Ciprofloxacin/administration & dosage , Ciprofloxacin/adverse effects , Colony Count, Microbial , Haemophilus influenzae/drug effects , Haemophilus influenzae/isolation & purification , Klebsiella/drug effects , Klebsiella/isolation & purification , Pneumonia, Bacterial/etiology , Prospective Studies , Sputum/microbiology , Staphylococcus aureus/drug effects , Staphylococcus aureus/isolation & purification , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/isolation & purification , Treatment OutcomeABSTRACT
Background: Samarium153 EDTMP, a beta and gamma emitter, is used in the palliative therapy of painful bone metastases. Aim: To evaluate the analgesic effects and myelotoxicity of Samarium153 EDTMP in patients with prostate, breast and renal carcinoma. Patients and methods: Twenty patients with bone metastases (11 males), aged 65 years old as a mean, received a 1 to 2 mCi/kg intravenous dose of Samarium153 EDTMP, produced in Chile. Patients were followed thereafter during 4 to 40 weeks. Pain was assessed using a visual analogue scale. Results: Pain decreased from a score of 6.4 prior to treatment, to 2.7 at the fourth week of therapy and the effect lasted a mean of 12.5 weeks. Myelotoxicity was observed in 68percent of cases (WHO stage I in 21 percent, stage II in 37 percent, stage III in 11percent and no patients in stage IV). Platelets were the most affected series and neutrophils the least affected. Cell counts returned to normal between the sixth and eighth week. Seventy nine percent of patients decreased their basal analgesic therapy at the sixth week and 88percent did so at the eighth week. Forty one percent of these patients discontinued all analgesics. Conclusions: Samarium153 EDTMP is effective in the treatment of pain in patients with bone metastases and its myelotoxicity is low to moderate. It should be considered as a therapy for this type of pain, with the precaution of performing periodical bood counts
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Samarium/pharmacokinetics , Bone Neoplasms/drug therapy , Neoplasm Metastasis/drug therapy , Radioisotopes/pharmacokinetics , Pain/drug therapy , AnalgesiaABSTRACT
La pesquisa y seguimiento de cardiotoxicidad secundaria a antraciclinas debe ser considerada, debido a su acción acumulativa y al grave pronóstico en casos con factores de riesgo. La ventriculografía radioisotópica permite: a) evaluar la función ventricular en forma seriada simple y reproducible; b) modificar la terapia, en caso de demostrarse alteración de fracción de eyección ventricular y/o indicar biopsia selectivamente